ARGX Argenx: Forward P/S Multiple
argenx SE is mitigating risks by developing therapies for a wide range of severe autoimmune pathologies. The forward P/S multiple reflects current market expectations, with the parameter set at 8.60. Growth is accelerating through partnerships with research centers and biopharmaceutical firms to launch new antibodies. Meanwhile, contractor production capacities are operating at peak efficiency, undergoing scheduled modernization without downtime.
ARGX (argenx BVBA): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ARGX - Net Financial Result|Projected Future Earnings argenx SE|ARGX - Market Cap to Earnings|Forward P/E Multiple Argenx|ARGX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization argenx BVBA|ARGX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) argenx|ARGX - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months argenx.com|ARGX - Earnings per share growth this year|Net earnings per share growth forecast for next year argenx SE
- company sales and revenue statistics:
Fundamental company valuation:argenx (ARGX)
The specifics of developing immunological drugs involving multi-year investments make the forward P/S ratio a key indicator for valuing the future monopoly of argenx SE (ARGX). This metric measures the risk of a valuation correction if financial targets are not met, where inflated values signal that the asset is overbought. The calculation is based on discounting expected revenue to the cost of capital, allowing the investor to determine the extent of market expectations currently priced in.
Competitor analysis for argenx SE
Forward P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Market Cap to Future Revenue Ratio|ADMA Bio - Forward P/S Multiple|PTGX - Forward P/S Multiple|Immunovant, Inc. (IMVT) - Price-to-Projected Revenue Ratio|kiniksa.com - Forward Price to Sales|GRFS (Grifols) - Forward P/S Multiple|ADPT - Projected Price to Revenue|Forward P/S Multiple CLDX|AUPH - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio BioCryst BCRX|VERA: Market Cap to Projected Revenue|DNTH: Forward Price-to-Revenue Multiple|PHVS (Pharvaris NV) - Market Cap to Projected Revenue|ABCL (AbCellera Biologics Inc) - Forward Price-to-Revenue Multiple|Tourmaline - Forward Price to Sales|Price-to-Projected Revenue Ratio Precigen, Inc.|pharming.com (PHAR) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NKTR|UPB - Market Cap to Future Revenue Ratio|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Forward P/S Multiple Immunome Bio IMNM|GOSS - Price-to-Projected Revenue Ratio|Forward Price to Sales KALV (kalvista.com)|SEPN: Forward P/S Multiple|Projected Price to Revenue Pieris Pharma PVLA|Forward Price-to-Revenue Multiple SVRA|Market Cap to Projected Revenue RIGL (Rigel Corp)|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS: Future Price to Revenue|Forward P/S Multiple ENGN (enGene)|Forward Price to Sales RAPT|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|tizianalifesciences.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Cabaletta Bio|Forward Price-to-Revenue Multiple Ventyx Biosciences Inc. (VTYX)|Forward P/S Multiple THTX|Forward P/S Multiple Avalo Therapeutics Inc (AVTX)|Eledon Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales AGEN|Climb Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio Zura Bio Ltd ZURA|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adagene Inc.|Price-to-Projected Revenue Ratio ImageneBio|Forward Price-to-Revenue Multiple Shattuck Therapeutics (STTK)|Forward Price-to-Revenue Multiple EQ (Equillium, Inc.)|Forward P/S Multiple connectbiopharm.com (CNTB)|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA: Market Cap to Projected Revenue|InflaRx GmbH - Forward P/S Multiple|Market Cap to Future Revenue Ratio x4pharma.com|ACET: Forward P/S Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|BRNS: Forward Price to Sales|Forward P/S Multiple KZR|sabbiotherapeutics.com (SABS) - Projected Price to Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Market Cap to Future Revenue Ratio|QTTB - Price-to-Projected Revenue Ratio|GOVX (GeoVax Corp) - Market Cap to Projected Revenue|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue IBIO|Forward Price-to-Revenue Multiple CARM|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Market Cap to Expected Sales Ratio hcwbiologics.com|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Market Cap to Future Revenue Ratio|Aditxt Corp - Forward P/S Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Vyome Therapeutics - Forward Price to Sales|REVB (Revelation Biosciences) - Forward P/S Multiple|INDP - Projected Price to Revenue|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|calcimedica.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK (Allakos Inc) - Future Price to Revenue|HOOKIPA - Forward P/S Multiple|Forward Price to Sales IGMS (IGM Biosciences, Inc.)|ITOS: Forward P/S Multiple|Ocean Biomedical Inc (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|THRD: Forward Price to Sales
